Verapamil Hydrochloride

Phase 3Small molecule

Mylan Pharmaceuticals Inc

Verapamil Hydrochloride is one of 56 small molecule programs targeting Keloid. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

KeloidActive, not recruiting

Cystic FibrosisNot yet recruiting

KeloidPreclinical

Active, not recruiting

Cystic FibrosisPhase 3

Not yet recruiting

Competition

Competitive Landscape

107 competitors in Cystic Fibrosis

#DrugCompanyPhaseTrials

Ibsrela

AArdelyx

Phase 3

1 2

Mycobutin

Pfizer

Phase 2

1 3

HSK31858

Haisco Pharmaceutical Group Co., Ltd.

Phase 3

2 4

ELX/TEZ/IVA

Vertex Pharmaceuticals

Phase 3

18 5

Trikafta

NNottingham University Hospitals NHS Trust

Phase 3

4 6

VNZ/TEZ/D-IVA

Vertex Pharmaceuticals

Phase 3

1 7

VX-121/TEZ/D-IVA

Vertex Pharmaceuticals

Phase 3

4 8

Verapamil Hydrochloride

Mylan Pharmaceuticals Inc

Phase 3

1 9

Hyperpolarized Xenon-129

TThunder Bay Regional Health Research Institute

Phase 3

1 10

Initiation of CFTR Modulator

CChildren's Hospital Medical Center, Cincinnati

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

ApprovedNot yet recruiting

Atrial Fibrillation (AF)

NCT07706075

Q3 2028

Phase 2Not yet recruiting

Cystic Fibrosis

NCT07688070

Clinical

Trials by Indication[1]

Keloid1 trial

Comparison of Intralesional Triamcinolone Acetonide Treatment With Intralesional Verapamil Hydrochloride in Keloids

Completed·MMuhammad Aamir Latif·N/A·NCT07420166·60 enrolled

Cardiovascular1 trial

A Study of the Pharmacokinetic and Pharmacodynamic Responses in Healthy and Altered Human Cardiovascular Systems

Terminated·—·Phase 1·NCT03098680·18 enrolled

Lymphoma1 trial

Brentuximab Vedotin, Cyclosporine, and Verapamil Hydrochloride in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma

Completed·—·Phase 1·NCT03013933·29 enrolled

Atrial Fibrillation (AF)1 trial

Verapamil Versus Metoprolol for Rate Control in Hemodynamically Stable Atrial Fibrillation With Rapid Ventricular Response

Not yet recruiting·MMuhammad Ali Javed·Approved·NCT07706075·120 enrolled

Cystic Fibrosis1 trial

The Effect of Verapamil on Beta Cell Function in Adolescents and Adults With Cystic Fibrosis-related Dysglycemia

Not yet recruiting·RRhode Island Hospital·Phase 2·NCT07688070·30 enrolled

1 more indication

Unspecified3 trials

Food Study of Verapamil HCl Extended-Release Capsules 300 mg and Verelan® PM Extended-Release Capsules 300 mg

Completed· Mylan Pharmaceuticals Inc logo

Mylan Pharmaceuticals Inc·Phase 1·NCT00648401·24 enrolled

Fasting Study of Verapamil HCl Extended-Release Capsules 300 mg to Verelan® PM Extended-Release Capsules 300 mg

Completed· Mylan Pharmaceuticals Inc logo

Mylan Pharmaceuticals Inc·Phase 1·NCT00648050·72 enrolled

Fasting Applesauce Study of Verapamil HCl Extended-Release Capsules 300 mg and Verelan® PM Extended-Release Capsules 300 mg

Completed· Mylan Pharmaceuticals Inc logo

Mylan Pharmaceuticals Inc·Phase 1·NCT00649805·24 enrolled

Sources

References

[1]
ClinicalTrials.gov — 8 trial records for Verapamil Hydrochloride. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Verapamil Hydrochloride compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Verapamil Hydrochloride. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Mylan Pharmaceuticals Inc company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Mylan Pharmaceuticals Inc

Verapamil Hydrochloride

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2027

Q3 2028

Trials by Indication[1]

Keloid1 trial

Cardiovascular1 trial

Lymphoma1 trial

Atrial Fibrillation (AF)1 trial

Cystic Fibrosis1 trial

Unspecified3 trials

References

Drug Info

Quick Facts

Related News